Advancing Stem Cell Science. Inspiring New Hope. 

Join us in Pursuing the Next Scientific Frontier of Battling Vascular Diseases

Come along
Hemostemix is committed to advancing scientific research on our patented process for cultivating ACP-01 autologous stem cells. Our goal is to bring new scientific breakthroughs and therapeutic options to market to help transform the lives of patients living with vascular diseases.
 
Once a study has been approved to start, we can notify you that the recruitment window is open and confirm eligibility requirements.
 
Want to be notified when a study is open for enrollment? Please follow this link. 
Yes, Notify Me

Part of the study development process includes securing approval by an Institutional Review Board (IRB), which under FDA regulations, is a group that has been formally designated to review and monitor biomedical research involving human subjects.

The following trials have been submitted for IRB review. 

Trials Submitted for Approval

PHASE 1 STUDY:

TREATMENT OF VASCULAR COGNITIVE IMPAIRMENT AND DEMENTIA WITH ANGIOGENIC CELL PRECURSORS 

The objective/hypothesis of this study is that the administration of the ACP-01 is safe and feasible for appropriate patient types. 

The investigators of this study propose that ACP-01 cells, derived from a hematopoietic cell lineage, have demonstrated molecular characteristics that favor the treatment of vascular cognitive impairment and dementia (VCID).

 

PHASE I STUDY:

BASKET PROTOCOL CLINICAL TRIAL OF ACP-01

 

This proposed basket protocol is designed to evaluate safety, feasibility, and early efficacy signals of ACP-01 in patients with:

  • Vascular dementia (earliest medically validated subtype)

  • Peripheral arterial disease (PAD)

  • Angina

  • Ischemic cardiomyopathy

  • Non-ischemic dilated cardiomyopathy

  • Congestive heart failure (CHF)

  • Total body ischemia

If you’d like to be notified when a study is open for enrollment, please complete the notification form below.

 

These studies will be investigational and the therapies under evaluation have not been approved for general use.

Submitting this form expresses interest only — it does not enroll you in a study, guarantee eligibility, or promise access to treatment. Final eligibility will be determined by the study protocol and an IRB-approved informed consent process.

About Hemostemix

Hemostemix (TSXV:HEM OTCQB:HMTXF FSE:2VFO) is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed and patented ACP-01 - an autologous (patient's own) blood-based stem cell therapy. Hemostemix has completed seven clinical studies of 318 subjects and published its results in 11 peer reviewed publications.

For further information, please contact: Thomas Smeenk, President, CEO & Co-Founder: EM: tsmeenk@hemostemix.com